JMJD2C (KDM4C) Chemiluminescent Assay Kit
The JMJD2C (KDM4C) Chemiluminescent Assay Kit is an ELISA (enzyme-linked immunosorbent assay)-based assay designed to measure the demethylase activity of JMJD2C (Jumonji domain-containing protein 2C) for screening and profiling applications. The JMJD2C (KDM4C) assay kit comes in a convenient 96-well format, with enough purified recombinant JMJD2C enzyme (amino acids 2-372), pre-coated plate with histone substrate, all the reagents necessary for assay detection and blocking buffer for 96 enzyme reactions.
- TBST Buffer (1x Tris-buffered saline, pH 8, containing 0.05% Tween-20)
- Luminometer or microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # |
Name | Amount | Storage |
| 50105 | JMJD2C, GST-Tag* | 20 µg | -80°C |
| 52140E | Primary Antibody 5 | 12.5 µl | -80°C |
| 52130H | Secondary HRP-Labeled Antibody 1 | 10 µl | -80°C |
| 4x JMJD2C Direct Assay Buffer | 3 x 1 ml | -80°C | |
| 52100 | Blocking Buffer 4 | 50 ml | +4°C |
| HRP Substrate A (translucent bottle) | 6 ml | Room Temp | |
| HRP Substrate B (brown bottle) | 6 ml | Room Temp | |
| White plate pre-coated with Histone-Substrate | 1 plate | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
JMJD2C (Jumonji domain -containing protein 2C), also known as KDM4C, belongs to the JMJD2 subfamily of JMJD histone lysine demethylase proteins. It is involved in demethylating H3K9me2/3, participating in epigenetic regulation. JMJD2C has been linked to colorectal cancer and uveal melanoma, where it also participates in cisplatin treatment resistance. JMJD2C promotes expression of MDM2 (mouse double minute-2 homolog) by demethylating its promoter. MDM2 in turn promotes the ubiquitination and degradation of p53 and increased levels of IL15Ra (interleukin 15 receptor subunit alpha), a pathway that supports cells to resist cisplatin treatment and uveal melanoma cell growth. The use of JMJD2C inhibitors is an area of interest that requires further development, and the development of active inhibitors will be beneficial in the cancer therapy field.
Manni W., et al., 2022 Signal Transduct Target Ther 7:304.
Zhu Q., et al., 2022 Cell Death Discovery 8:227.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.